Millions of diabetic patients use medications that stimulate the pancreas to make more insulin. Now, the FDA is investigating if these medications can over-stimulate the pancreas and lead to side effects like pancreatitis and pancreatic cancer.
Need a Texas Pancreatic Cancer Lawyer? Collen A. Clark is a true advocate for his clients and is passionate about helping Texans that have been injured or wronged. If you or a loved one was injured by incretin therapy, you should contact our lawyers immediately. You may be entitled to compensation by filing a lawsuit.
Incretin Therapy and Pancreatic Cancer
Diabetes drugs in the incretin mimetic class mimic digestive hormones called incretins, which increase the release of insulin from the pancreas to control blood-sugar levels.
Unfortunately, some experts are concerned that incretin therapy could over-stimulate the pancreas and cause inflammation, pancreatitis, or even pancreatic cancer. In March 2013, the FDA opened a safety investigation and issued warnings about two concerning studies.
One of those studies was published in Diabetes, the journal of the American Diabetes Association. Researchers autopsied pancreases from deceased patients who used incretin therapy for at least one year. Several of the pancreases had pre-cancerous growths that could become malignant or require surgery to remove.
Incretin therapy diabetes medications include:
- Exenatide (Byetta, Bydureon)
- Liraglutide (Victoza)
- Sitagliptin (Januvia, Janumet, Janumet XR, Juvisync)
- Saxagliptin (Onglyza, Kombiglyze XR)
- Alogliptin (Nesina, Kazano, Oseni)
- Linagliptin (Tradjenta, Jentadueto)
Hundreds of Lawsuits Centralized in Diabetes Drug MDL
Hundreds of lawsuits have been filed by people who were injured by incretin therapy, but not as part of a class action. Instead, they are individual lawsuits that have been centralized in a federal Multi-District Litigation (MDL No. 2452) in the Southern District of California — In Re: Incretin Mimetics Products Liability Litigation MDL. The MDL was created in August 2013, and by January 2016 it contained over 750 lawsuits involving people injured by incretin therapy.
What is the problem?
The Clark Firm, LLP is nationally recognized as a class action law firm. However, our attorneys are not filing a pancreatic cancer class action. We are filing individual lawsuits for people who were injured by diabetes medications in the incretin therapy class.
About Class Actions
Class actions are the most efficient way to resolve legal disputes involving a large group of people with very similar claims. Members choose a “class representative” and collectively seek compensation. Any payout awarded by a jury or settlement is divided equally among everyone who joins the lawsuit.
Why Our Law Firm is Filing Individual Lawsuits as Opposed to a Class Action
The problem with class actions is that members may have to accept a “low-ball” settlement or attorneys’ fees that do not leave much remaining for everyone in the lawsuit to share. Another problem is that class actions are not intended to maximize compensation for people with the most severe injuries from dangerous medications.
Instead of a class action, our attorneys are filing individual lawsuits against negligent drug-makers for failing to warn about severe side effects. If you were diagnosed with pancreatic cancer, we may be able to help you file a lawsuit and seek compensation for your pain and suffering, past and future medical expenses, and more.
Need a Pancreatic Cancer Lawyer in Texas?
Collen A. Clark is a true advocate for his clients and is passionate about helping Texans that have been injured or wronged.
Collen’s amazing success in the courtroom and well known dedication to his clients has earned him the recognition of his peers as one of The Top Trial Lawyers in Texas.”
The Clark Firm has assembled a team of trial lawyers with more than 100 years experience, participation in over 600 jury trials and $260 million in verdicts and/or settlements. Please use the form below to contact our Texas pancreatic cancer lawyers for a free lawsuit review.